Quarterly report pursuant to Section 13 or 15(d)

Schedule of Share Based Compensation Activity (Details)

v3.21.1
Schedule of Share Based Compensation Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Subsidiary, Sale of Stock [Line Items]    
Number of Options, Beginning Balance 756,383 509,173
Weighted average exercise price, Beginning Balance $ 1.82 $ 1.30
Weighted average remaining contractual term, Beginning Balance 7 years 4 months 24 days
Number of Options, Granted 1,229,590
Weighted average exercise price, Granted $ 4.61
Number of Options, Additional options grant StemoniX holders 292,995
Weighted average exercise price, Additional options grant StemoniX holders $ 4.61
Number of Options, assumed in Merger 55,840
Weighted average exercise price, Options assumed in Merger $ 45.95
Number of Options, Exercised (29,916) (12,000)
Weighted average exercise price, Exercised $ 1.24 $ 1.94
Number of Options, Forfeited (29,349) (12,438)
Weighted average exercise price, Forfeited $ 2.00 $ 1.35
Number of Options, Expired (7,000) (6,125)
Weighted average exercise price, Expired $ 1.39 $ 1.24
Number of Options, Ending Balance 2,268,543 478,610
Weighted average exercise price, Ending Balance $ 4.79 $ 1.28
Weighted average remaining contractual term, Ending Balance 8 years 1 month 6 days 6 years 6 months
Number of Options, Exercisable 390,109  
Weighted average exercise price, Exercisable $ 8.00  
Weighted average remaining contractual term, Exercisable 7 years 6 months  
Stock-based compensation $ 366 $ 72
Stock Options [Member]    
Subsidiary, Sale of Stock [Line Items]    
Stock-based compensation 366 42
Shares Issued to Non Employees [Member]    
Subsidiary, Sale of Stock [Line Items]    
Stock-based compensation $ 30